<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Endocrinol Metab (Seoul)</journal-id><journal-id journal-id-type="publisher-id">ENM</journal-id><journal-title-group><journal-title>Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2093-596X</issn><issn pub-type="epub">2093-5978</issn><publisher><publisher-name>Korean Endocrine Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27491719</article-id><article-id pub-id-type="pmc">5053058</article-id><article-id pub-id-type="doi">10.3803/EnM.2016.31.3.446</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Clinical Study</subject></subj-group></subj-group></article-categories><title-group><article-title>Prevalence of Reduced Kidney Function by Estimated Glomerular Filtration Rate Using an Equation Based on Creatinine and Cystatin C in Metabolic Syndrome and Its Components in Korean Adults</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-1215-7975</contrib-id><name><surname>Kang</surname><given-names>Yang Ho</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Dong Wook</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-3878-9030</contrib-id><name><surname>Son</surname><given-names>Seok Man</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea.</aff><aff id="A2"><label>2</label>Research Institute for Convergence of Biomedical Science and Technology, Pusan National University School of Medicine, Yangsan, Korea.</aff><aff id="A3"><label>3</label>Department of Family Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.</aff><author-notes><corresp>Corresponding author: Yang Ho Kang. Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea. Tel: +82-55-360-2358, Fax: +82-55-360-2150, <email>kangyh@pusan.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>02</day><month>8</month><year>2016</year></pub-date><volume>31</volume><issue>3</issue><fpage>446</fpage><lpage>453</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>16</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Korean Endocrine Society</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>It is known that metabolic syndrome (MetS) is associated with chronic kidney disease. We evaluated and compared the prevalence of reduced kidney function in MetS and its components by estimated glomerular filtration rate (eGFR) using an equation based on creatinine (eGFRcr), cystatin C (eGFRcys), and combined creatinine-cystatin C (eGFRcr-cys) in Korean adults.</p></sec><sec><title>Methods</title><p>We analyzed data from 3,649 adults who participated in a comprehensive health examination.</p></sec><sec><title>Results</title><p>Mean values of eGFRcys were higher compared with mean values of eGFRcr (96.1&#x000b1;18.2 mL/min/1.73 m<sup>2</sup> vs. 91.2&#x000b1;13.6 mL/min/1.73 m<sup>2</sup>) in total subjects. The prevalence of reduced kidney function increased with age (9.6% for eGFRcys vs. 5.8% for eGFRcr-cys vs. 4.9% for eGFRcr, in subjects aged &#x02265;60 years), and significantly increased with MetS, abdominal obesity, hypertension, high triglyceride, low high density lipoprotein (HDL), and high insulin resistance. The prevalence of MetS, abdominal obesity, hypertension, high insulin resistance, low HDL, and hepatic steatosis was significantly increased in subjects with reduced kidney function. This increased prevalence and the odds ratio of reduced kidney function for prevalence of MetS was highest for eGFRcys, followed by those of eGFRcr-cys, and eGFRcr.</p></sec><sec><title>Conclusion</title><p>The prevalence of reduced kidney function by eGFR was significantly increased in subjects with MetS and its related components. eGFRcys and eGFRcr-cys were superior to eGFRcr in detecting reduced kidney function.</p></sec></abstract><kwd-group><kwd>Glomerular filtration rate</kwd><kwd>Cystatin C</kwd><kwd>Creatinine</kwd><kwd>Metabolic syndrome</kwd></kwd-group><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>Pusan National University Yangsan Hospital</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Metabolic syndrome (MetS), a constellation of cardiovascular disease (CVD) risk factors [<xref rid="B1" ref-type="bibr">1</xref>] is associated with risk of coronary heart disease, stroke, and cardiovascular related mortality [<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref>]. Moreover, MetS is associated with progression to chronic kidney disease (CKD) [<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref>]. The glomerular filtration rate (GFR) is considered the most widely used index of overall kidney function and is estimated rather than measured in clinical practice. Generally, estimation of GFR from equations based on serum creatinine level is the most common method. However, creatinine is affected by age, sex, race, muscle mass, and diet [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref>].</p><p>Recently, serum cystatin C, an endogenous protein, which is freely filtered by the glomerulus, reabsorbed, and catabolized, but not secreted by the renal tubules [<xref rid="B9" ref-type="bibr">9</xref>], has been proposed as a potential alternative for serum creatinine as a filtration marker [<xref rid="B10" ref-type="bibr">10</xref>]. Cystatin C is less affected by age, race, muscle mass, and diet [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B11" ref-type="bibr">11</xref>]. However, body mass index (BMI), diabetes, and inflammation affect cystatin C level independent of kidney function [<xref rid="B12" ref-type="bibr">12</xref>]. Tsai et al. [<xref rid="B13" ref-type="bibr">13</xref>] estimated GFR (eGFR) using equations based on creatinine (eGFRcr) and cystatin C (eGFRcys) and compared the discordance of the equations using the two filtration markers in evaluating the prevalence of reduced kidney function and incident all-cause and cardiovascular mortality among persons with diabetes in the United States. However, few studies have evaluated the prevalence of reduced kidney function in MetS or compared equations based on creatinine and cystatin C to eGFR as an indicator of kidney function especially in an Asian population.</p><p>The aim of this study was to evaluate and compare the prevalence of reduced kidney function in MetS and related metabolic components by eGFR using an equation based on eGFRcr, eGFRcys, and combined creatinine-cystatin C (eGFRcr-cys).</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Subjects</title><p>We analyzed data from 3,649 adults aged &#x02265;20 years who participated in a comprehensive health examination at Pusan National University Yangsan Hospital in Yangsan, Korea in 2013. Of the subjects, we excluded those with liver disease (serum levels of aspartate aminotransferase or alanine aminotransferase greater than three times the upper limit of the reference range) (<italic>n</italic>=19), abnormal serum thyroid stimulating hormone (TSH) levels (TSH &#x0003c;0.27 &#x000b5;IU/mL or TSH &#x0003e;4.2 &#x000b5;IU/mL; <italic>n</italic>=473), or elevated high-sensitivity C-reactive protein (hs-CRP) level (&#x0003e;10.0 mg/L; <italic>n</italic>=3). Finally, 3,154 adults (1,871 men, 1,283 women) were enrolled in the study. No subject had an eGFR lower than 15 mL/min/1.73 m<sup>2</sup> or an eGFR higher than 200 mL/min/1.73 m<sup>2</sup>.</p><p>Informed consent for use of the health screening data analyzed in this study was obtained from all subjects. This study was approved by the Institutional Review Board of Pusan National University Yangsan Hospital (subject no. 05-2016-025).</p></sec><sec><title>Anthropometric and biochemical data</title><p>Height and weight were measured with subjects barefoot and wearing light weight clothing. BMI was calculated as weight in kilograms divided by the square of height in meters. Waist circumference was measured with a soft tape measure on standing subjects midway between the lowest rib and the iliac crest. Blood pressure was measured on the right arm with subjects in a seated position after a 5-minute rest. Blood specimens were collected from the antecubital vein after an overnight fast. Fasting blood glucose (FBG) was measured by the glucose oxidase method (Synchron LX-20, Beckman Coulter Inc., Fullerton, CA, USA). Concentrations of standard liver enzymes, total cholesterol, high density lipoprotein (HDL) cholesterol, serum triglyceride (TG), &#x003b3;-glutamyltransferase (GGT), and serum creatinine (Jaffe's kinetic assay) were measured using an autoanalyzer and an enzymatic colorimetric method (Hitachi 7600, Hitachi Ltd., Tokyo, Japan). The serum cystatin C level was measured by the latex agglutination test (Modular P800, Roche Diagnostics, Mannheim, Germany).</p></sec><sec><title>Estimating equations</title><p>GFR was estimated using equations developed by the CKD-epidemiology collaboration (CKD-EPI). eGFRcr was computed using the CKD-EPI creatinine 2009 equation [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B14" ref-type="bibr">14</xref>]. eGFRcys and eGFRcr-cys [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B15" ref-type="bibr">15</xref>] were used to assess the most accurate estimate of GFR and were computed using the CKD-EPI cystatin C 2012 equation and the CKD-EPI creatinine-cystatin C 2012 equation, respectively [<xref rid="B10" ref-type="bibr">10</xref>].</p></sec><sec><title>Definitions</title><p>Reduced kidney function was defined as eGFR &#x0003c;60 mL/min/1.73 m<sup>2</sup>. MetS was defined according to the modified, revised National Cholesterol Education Program Adult Treatment III [<xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref>] as the presence of three or more of the following criteria: (1) abdominal obesity defined as waist circumference &#x02265;90 cm in men and &#x02265;80 cm in women; (2) impaired fasting glucose as defined by FBG &#x02265;100 mg/dL; (3) high TG as defined by TG &#x02265;150 mg/dL (for conversion to mmol/L, multiply by 0.01129); (4) low HDL as defined by HDL &#x0003c;40 mg/dL in men and &#x0003c;50 mg/dL in women (for conversion to mmol/L, multiply by 0.02586); and (5) blood pressure &#x02265;130/85 mm Hg. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated using the following formula: <disp-formula>HOMA-IR=[fasting serum insulin (mU/L)&#x000d7;fasting plasma glucose (mmol/L)]/22.5</disp-formula></p><p>High insulin resistance was defined as an HOMA-IR score higher than the 75th percentile [<xref rid="B18" ref-type="bibr">18</xref>]. Fatty liver index (FLI) was calculated as below [<xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref>], and an FLI &#x02265;60 was considered to indicate hepatic steatosis: <disp-formula>FLI=[e0.953&#x000d7;loge (TG)+0.139&#x000d7;BMI+0.718&#x000d7;loge (GGT)+0.053&#x000d7;waist circumference&#x02013;15.745)]/[1+e0.953&#x000d7;loge (TG)+0.139&#x000d7;BMI+0.718&#x000d7;loge (GGT)+0.053&#x000d7;waist circumference&#x02013;15.745]&#x000d7;100</disp-formula></p></sec><sec><title>Statistical analysis</title><p>All data are presented as mean&#x000b1;SD for continuous variables. Median values are also indicated in the cases of TG, GGT, and hs-CRP, which had skewed distributions. Categorical variables were compared using the chi-square test. Odds ratio (OR) and corresponding 95% confidence interval (CI) as an estimate of the relative risk of reduced kidney function for the prevalence of MetS were calculated by multiple logistic regression analyses with non-adjusted data (model 1), after adjusting for age (20 to 39, 40 to 59, &#x02265;60 years) and sex (men, women) (model 2), and after adjusting for age, sex, abdominal obesity (yes, no), and high fasting glucose (yes, no) (model 3), using preserved kidney function (eGFR &#x02265;60 mL/min/1.73 m<sup>2</sup>) as the reference category. Statistical analyses were performed with the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A probability value less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Clinical characteristics</title><p>The prevalence of MetS was 26.9% in men and 18.2% in women. Men showed higher mean levels of serum creatinine (0.97&#x000b1;0.14 mg/dL vs. 0.7&#x000b1;0.1 mg/dL, <italic>P</italic>&#x0003c;0.001) and serum cystatin C (0.89&#x000b1;0.16 mg/dL vs. 0.80&#x000b1;0.18 mg/dL, <italic>P</italic>&#x0003c;0.001) than women. Mean eGFRcys was higher than mean eGFRcr (96.1&#x000b1;18.2 mL/min/1.73 m<sup>2</sup> vs. 91.2&#x000b1;13.6 mL/min/1.73 m<sup>2</sup>, respectively), with mean eGFRcr-cys falling between them (94.5&#x000b1;15.4 mL/min/1.73 m<sup>2</sup>) in total subjects (<xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec><title>The prevalence of reduced kidney function by eGFRcr, eGFRcys, and eGFRcr-cys</title><p>With an increase in age, the prevalence of reduced kidney function increased and was highest for eGFRcys, intermediate for eGFRcr-cys, and lowest for eGFRcr (9.6% for eGFRcys vs. 5.8% for eGFRcr-cys vs. 4.9% for eGFRcr, <italic>P</italic>&#x0003c;0.001 in subjects aged &#x02265;60 years) (<xref ref-type="table" rid="T2">Table 2</xref>). With regard to metabolic parameters, the prevalence of reduced kidney function was significantly increased in subjects with MetS, abdominal obesity, hypertension, high TG, low HDL, and high insulin resistance and was highest for eGFRcys, intermediate for eGFRcr-cys, and lowest for eGFRcr (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec><title>Prevalence of MetS and its components between subjects with reduced kidney function and those with preserved kidney function by eGFRcr, eGFRcys, and eGFRcr-cys</title><p>The prevalence of MetS (34.5% vs. 23.1% in eGFRcr, 36.9% vs. 22.9% in eGFRcys, 36.7% vs. 23.1% in eGFRcr-cys), abdominal obesity (63.6% vs. 45.5% in eGFRcr, 68.9% vs. 45.0% in eGFRcys, 70.0% vs. 45.3% in eGFRcr-cys), hypertension (43.6% vs. 31.2% in eGFRcr, 42.7% vs. 31.1% in eGFRcys, 45.0% vs. 31.2% in eGFRcr-cys), high insulin resistance (41.8% vs. 24.7% in eGFRcr, 39.8% vs. 24.5% in eGFRcys, 38.3% vs. 24.7% in eGFRcr-cys), and hepatic steatosis (29.1% vs. 18.0% in eGFRcr, 27.2% vs. 17.9% in eGFRcys, 26.7% vs. 18.0% in eGFRcr-cys) was significantly increased in subjects with reduced kidney function compared with subjects with preserved kidney function. In case of low HDL, the increased prevalence was only significant in eGFRcys and eGFRcr-cys (16.4% vs. 17.9% in eGFRcr, 32.0% vs. 17.4% in eGFRcys, 30.0% vs. 17.7% in eGFRcr-cys) (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p></sec><sec><title>OR (95% CI) of reduced kidney function for prevalence of MetS according to eGFRcr, eGFRcys, and eGFRcr-cys</title><p>In comparison of relative risk of reduced kidney function for prevalence of MetS, eGFRcys was the highest (OR, 1.97; 95% CI, 1.30 to 2.96; <italic>P</italic>=0.001), followed by eGFRcr-cys (OR, 1.93; 95% CI, 1.13 to 3.28; <italic>P</italic>=0.015) and eGFRcr (OR, 1.75; 95% CI, 1.00 to 3.07; <italic>P</italic>=0.050) in the non-adjusted model. However, it was attenuated after adjusting for age and sex (model 1) and for age, sex, abdominal obesity, and high fasting glucose (model 2) (<xref ref-type="table" rid="T3">Table 3</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study, we evaluated and compared the prevalence of reduced kidney function in subjects with MetS and its related parameters by eGFRcr, eGFRcys, and eGFRcr-cys in Korean adults. The mean value of eGFRcys (96.1&#x000b1;18.2 mL/min/1.73 m<sup>2</sup>) was higher than the mean value of eGFRcr (91.2&#x000b1;13.6 mL/min/1.73 m<sup>2</sup>). This finding was consistent with previous large scale studies [<xref rid="B13" ref-type="bibr">13</xref><xref rid="B21" ref-type="bibr">21</xref>] from the National Health and Nutrition Examination Survey in the United States and study [<xref rid="B22" ref-type="bibr">22</xref>] using data from an Italian population. This finding might be due to more disperse distributions of eGFRcys than eGFRcr and differences in non-GFR determinants, such as BMI, between serum cystatin C and creatinine levels [<xref rid="B21" ref-type="bibr">21</xref><xref rid="B23" ref-type="bibr">23</xref>].</p><p>Similar to previous results [<xref rid="B21" ref-type="bibr">21</xref><xref rid="B24" ref-type="bibr">24</xref>], there was an increase in the prevalence of reduced eGFR with age in our study. Pattaro et al. [<xref rid="B22" ref-type="bibr">22</xref>] reported that correlation of eGFRcys and eGFRcr was significantly different in those &#x02265;65 years compared to in those &#x0003c;65 years. Tsai et al. [<xref rid="B13" ref-type="bibr">13</xref>] showed that the absolute difference in reduced kidney function prevalence between eGFRcys and eGFRcr was 6.9% in those aged 60 to 80 years and 10.3% in those aged 80 years or older. Similarly, the discrepancy in the prevalence of reduced kidney function between eGFRcys and eGFRcr was largest in those aged &#x02265;60 years (38%) compared to those aged 40 to 59 years (11%) in this study. A possible reason for the increased prevalence of reduced kidney function by eGFRcys than eGFRcr in older age (9.6% vs. 5.8%, <italic>P</italic>&#x0003c;0.001 in aged &#x02265;60 years respectively) could be that muscle mass and diet are significant non-GFR determinants in the case of creatinine, and eGFRcr may be confounded by cachexia and muscle wasting at older ages [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B21" ref-type="bibr">21</xref>]. Furthermore, serum cystatin C is known to have a higher association with mortality and CVD than serum creatinine, especially in older adults [<xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">27</xref>]. Therefore, our finding suggests that cystatin C is a better filtration marker than creatinine in elderly persons [<xref rid="B12" ref-type="bibr">12</xref><xref rid="B15" ref-type="bibr">15</xref>].</p><p>In the present study, we demonstrated that the prevalence of reduced kidney function was significantly increased and higher when using eGFRcys than eGFRcr in subjects with MetS, abdominal obesity, hypertension, low HDL, and high insulin resistance. In addition, the prevalence of MetS, abdominal obesity, hypertension, high insulin resistance, and hepatic steatosis was significantly increased in subjects with reduced kidney function compared to those with preserved kidney function, and the percentage was higher according to eGFRcys than eGFRcr. Previous studies have demonstrated that cystatin C had stronger associations than creatinine with systolic blood pressure, weight, and BMI [<xref rid="B12" ref-type="bibr">12</xref>], and eGFRcys were more accurate, sensitive, and specific in overweight and obese subjects including visceral obesity compared to eGFR equations based on creatinine [<xref rid="B28" ref-type="bibr">28</xref><xref rid="B29" ref-type="bibr">29</xref>]. It was also shown that cystatin C may be a sensitive marker of small reductions in kidney function (preclinical kidney disease) [<xref rid="B30" ref-type="bibr">30</xref>], and eGFRcys may be more reliable than eGFRcr, particularly in subjects with a mild reduction in GFR, in whom changes in serum creatinine are not detected [<xref rid="B7" ref-type="bibr">7</xref><xref rid="B31" ref-type="bibr">31</xref>]. MetS and its related components such as obesity, hypertension, dyslipidemia, and insulin resistance were also important in increased risk of CKD [<xref rid="B32" ref-type="bibr">32</xref>]. The possible pathophysiologic mechanism of the strong association between MetS and advancing CKD is that obesity, insulin resistance, hypertension, dyslipidemia, and inflammation result in increased expression of adipocytokines, angiotensin, and inflammatory cytokines and have been identified as causes of renal inflammation and fibrosis [<xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr">33</xref>]. Hepatic steatosis is now also considered to be a component of MetS [<xref rid="B34" ref-type="bibr">34</xref>] and has an association with advancing CKD [<xref rid="B35" ref-type="bibr">35</xref>]. Hence, these earlier reports may provide explanations for our findings. Diabetes is also an important factor, has a strong association with cystatin C [<xref rid="B36" ref-type="bibr">36</xref><xref rid="B37" ref-type="bibr">37</xref>], and is one of the non-GFR determinants for eGFRcys [<xref rid="B12" ref-type="bibr">12</xref>]. Tsai et al. [<xref rid="B13" ref-type="bibr">13</xref>] showed that the prevalence of reduced kidney function was almost three times higher in persons with diabetes compared to those without diabetes (eGFRcys 22.0% vs. 7.9%, eGFRcr 16.5% vs. 5.8%). However, in our study, there was no significant difference in the prevalence of reduced kidney function compared to preserved kidney function in subjects with high fasting glucose. Additionally, the percentage of reduced kidney function by eGFRcys (3.6%) was higher than that by eGFRcr (2.0%) in those with high fasting glucose, but showed a weak significance. The possible reason for this finding might be that enrolled subjects in this study were mostly healthy and hyperglycemia was defined by fasting glucose only. Therefore, the number of actual diabetic patients would be very small in our data.</p><p>In comparison of relative risk of reduced kidney function for prevalence of MetS, eGFRcys was also higher than eGFRcr in a non-adjusted model, although it was attenuated after adjusting for the non-GFR determinants of both filtration markers including age, sex, abdominal obesity, and high fasting glucose.</p><p>The eGFRcr-cys has been suggested as a useful and confirmatory test for CKD, because it performed better than equations based on either of these markers alone [<xref rid="B10" ref-type="bibr">10</xref><xref rid="B15" ref-type="bibr">15</xref><xref rid="B21" ref-type="bibr">21</xref>]. In this study, the values of eGFRcr-cys were higher than those of eGFRcr but lower than those of eGFRcys in all performed analyses. These results support suggestion that the combination of creatinine and cystatin C is a more accurate tool for eGFR due to over-estimation using cystatin C alone or under-estimation using creatinine alone.</p><p>Our study has some limitations. First, serum cystatin C and creatinine were measured only once. Second, direct-measured GFR was not performed, and we could not compare direct-measured GFR with eGFR as determined by the three equations to assess approximation to true kidney function. Third, we could not analyze social data such as exercise, diet, smoking, and medication use for previously diagnosed hypertension and/or hyperlipidemia, which could affect the prevalence of MetS and its related components, and serum levels of creatinine and cystatin C.</p><p>In conclusion, the prevalence of reduced kidney function by eGFR was significantly increased in subjects with MetS and its related components. eGFRcys and eGFRcr-cys were superior to eGFRcr in detecting the prevalence of reduced kidney function.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This study was supported by a Clinical Research Grant (2015) of Pusan National University Yangsan Hospital.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST:</bold> No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>P</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name></person-group><collab>IDF Epidemiology Task Force Consensus Group</collab><article-title>The metabolic syndrome: a new worldwide definition</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1059</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">16182882</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name></person-group><article-title>Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>1769</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">15983333</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obunai</surname><given-names>K</given-names></name><name><surname>Jani</surname><given-names>S</given-names></name><name><surname>Dangas</surname><given-names>GD</given-names></name></person-group><article-title>Cardiovascular morbidity and mortality of the metabolic syndrome</article-title><source>Med Clin North Am</source><year>2007</year><volume>91</volume><fpage>1169</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">17964915</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Hamm</surname><given-names>LL</given-names></name><name><surname>Jones</surname><given-names>DW</given-names></name><name><surname>Batuman</surname><given-names>V</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><etal/></person-group><article-title>The metabolic syndrome and chronic kidney disease in U.S. adults</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">14757614</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurella</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>JC</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name></person-group><article-title>Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>2134</fpage><lpage>2140</lpage><pub-id pub-id-type="pmid">15901764</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanauchi</surname><given-names>M</given-names></name><name><surname>Kanauchi</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name></person-group><article-title>Associations of chronic kidney disease with the metabolic syndrome in non-diabetic elderly</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>3608</fpage><lpage>3609</lpage><pub-id pub-id-type="pmid">16861728</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>MA</given-names></name><name><surname>Waikar</surname><given-names>SS</given-names></name></person-group><article-title>Established and emerging markers of kidney function</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><fpage>680</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">22311920</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew-Harris</surname><given-names>JS</given-names></name><name><surname>Florkowski</surname><given-names>CM</given-names></name><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Elmslie</surname><given-names>JL</given-names></name><name><surname>Endre</surname><given-names>ZH</given-names></name></person-group><article-title>The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men</article-title><source>Ann Clin Biochem</source><year>2013</year><volume>50</volume><issue>Pt 1</issue><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">23129724</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laterza</surname><given-names>OF</given-names></name><name><surname>Price</surname><given-names>CP</given-names></name><name><surname>Scott</surname><given-names>MG</given-names></name></person-group><article-title>Cystatin C: an improved estimator of glomerular filtration rate?</article-title><source>Clin Chem</source><year>2002</year><volume>48</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">11978596</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inker</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Tighiouart</surname><given-names>H</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><etal/></person-group><article-title>Estimating glomerular filtration rate from serum creatinine and cystatin C</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22762315</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangri</surname><given-names>N</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Beck</surname><given-names>GJ</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><etal/></person-group><article-title>Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">20980977</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Beck</surname><given-names>GJ</given-names></name><name><surname>Joffe</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Factors other than glomerular filtration rate affect serum cystatin C levels</article-title><source>Kidney Int</source><year>2009</year><volume>75</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">19119287</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CW</given-names></name><name><surname>Grams</surname><given-names>ME</given-names></name><name><surname>Inker</surname><given-names>LA</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name></person-group><article-title>Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">24271191</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Castro</surname><given-names>AF</given-names><suffix>3rd</suffix></name><name><surname>Feldman</surname><given-names>HI</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">19414839</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>Froissart</surname><given-names>M</given-names></name><name><surname>Kusek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>51</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">18295055</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab><article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2486</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">11368702</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><name><surname>Donato</surname><given-names>KA</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>2735</fpage><lpage>2752</lpage><pub-id pub-id-type="pmid">16157765</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name></person-group><article-title>Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">18957533</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedogni</surname><given-names>G</given-names></name><name><surname>Bellentani</surname><given-names>S</given-names></name><name><surname>Miglioli</surname><given-names>L</given-names></name><name><surname>Masutti</surname><given-names>F</given-names></name><name><surname>Passalacqua</surname><given-names>M</given-names></name><name><surname>Castiglione</surname><given-names>A</given-names></name><etal/></person-group><article-title>The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population</article-title><source>BMC Gastroenterol</source><year>2006</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type="pmid">17081293</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedogni</surname><given-names>G</given-names></name><name><surname>Kahn</surname><given-names>HS</given-names></name><name><surname>Bellentani</surname><given-names>S</given-names></name><name><surname>Tiribelli</surname><given-names>C</given-names></name></person-group><article-title>A simple index of lipid overaccumulation is a good marker of liver steatosis</article-title><source>BMC Gastroenterol</source><year>2010</year><volume>10</volume><fpage>98</fpage><pub-id pub-id-type="pmid">20738844</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grams</surname><given-names>ME</given-names></name><name><surname>Juraschek</surname><given-names>SP</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Foster</surname><given-names>MC</given-names></name><name><surname>Inker</surname><given-names>LA</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>62</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">23619125</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattaro</surname><given-names>C</given-names></name><name><surname>Riegler</surname><given-names>P</given-names></name><name><surname>Stifter</surname><given-names>G</given-names></name><name><surname>Modenese</surname><given-names>M</given-names></name><name><surname>Minelli</surname><given-names>C</given-names></name><name><surname>Pramstaller</surname><given-names>PP</given-names></name></person-group><article-title>Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association</article-title><source>Nephron Clin Pract</source><year>2013</year><volume>123</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">23797027</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vupputuri</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name></person-group><article-title>Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><fpage>993</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">19394726</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Manzi</surname><given-names>J</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Eggers</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prevalence of chronic kidney disease in the United States</article-title><source>JAMA</source><year>2007</year><volume>298</volume><fpage>2038</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">17986697</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Seliger</surname><given-names>SL</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Cystatin C and the risk of death and cardiovascular events among elderly persons</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2049</fpage><lpage>2060</lpage><pub-id pub-id-type="pmid">15901858</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarnak</surname><given-names>MJ</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Stehman-Breen</surname><given-names>CO</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Jenny</surname><given-names>NS</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Cystatin C concentration as a risk factor for heart failure in older adults</article-title><source>Ann Intern Med</source><year>2005</year><volume>142</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">15809461</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Stehman-Breen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">16908914</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marwyne</surname><given-names>MN</given-names></name><name><surname>Loo</surname><given-names>CY</given-names></name><name><surname>Halim</surname><given-names>AG</given-names></name><name><surname>Norella</surname><given-names>K</given-names></name><name><surname>Sulaiman</surname><given-names>T</given-names></name><name><surname>Zaleha</surname><given-names>MI</given-names></name></person-group><article-title>Estimation of glomerular filtration rate using serum cystatin C in overweight and obese subjects</article-title><source>Med J Malaysia</source><year>2011</year><volume>66</volume><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">22299549</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franca</surname><given-names>AK</given-names></name><name><surname>Dos Santos</surname><given-names>AM</given-names></name><name><surname>Salgado</surname><given-names>JV</given-names></name><name><surname>Hortegal</surname><given-names>EV</given-names></name><name><surname>da Silva</surname><given-names>AA</given-names></name><name><surname>Salgado Filho</surname><given-names>N</given-names></name></person-group><article-title>Estimated visceral adipose tissue, but not body mass index, is associated with reductions in glomerular filtration rate based on cystatin C in the early stages of chronic kidney disease</article-title><source>Int J Nephrol</source><year>2014</year><volume>2014</volume><fpage>574267</fpage><pub-id pub-id-type="pmid">24876964</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharnidharka</surname><given-names>VR</given-names></name><name><surname>Kwon</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>G</given-names></name></person-group><article-title>Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis</article-title><source>Am J Kidney Dis</source><year>2002</year><volume>40</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">12148093</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herget-Rosenthal</surname><given-names>S</given-names></name><name><surname>Bokenkamp</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>W</given-names></name></person-group><article-title>How to estimate GFR-serum creatinine, serum cystatin C or equations?</article-title><source>Clin Biochem</source><year>2007</year><volume>40</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">17234172</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Kari</surname><given-names>JA</given-names></name></person-group><article-title>Metabolic syndrome and chronic kidney disease</article-title><source>Curr Opin Nephrol Hypertens</source><year>2013</year><volume>22</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">23340215</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhowmik</surname><given-names>D</given-names></name><name><surname>Tiwari</surname><given-names>SC</given-names></name></person-group><article-title>Metabolic syndrome and chronic kidney disease</article-title><source>Indian J Nephrol</source><year>2008</year><volume>18</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">20368911</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>G</given-names></name><name><surname>Saldalamacchia</surname><given-names>G</given-names></name><name><surname>Conca</surname><given-names>P</given-names></name><name><surname>Arena</surname><given-names>A</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease: further expression of the metabolic syndrome</article-title><source>J Gastroenterol Hepatol</source><year>2007</year><volume>22</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">17295757</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcuccilli</surname><given-names>M</given-names></name><name><surname>Chonchol</surname><given-names>M</given-names></name></person-group><article-title>NAFLD and chronic kidney disease</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahakyan</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Shankar</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name></person-group><article-title>Serum cystatin C and the incidence of type 2 diabetes mellitus</article-title><source>Diabetologia</source><year>2011</year><volume>54</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">21380596</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>EH</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Jeong</surname><given-names>DW</given-names></name><name><surname>Son</surname><given-names>SM</given-names></name><name><surname>Kang</surname><given-names>YH</given-names></name></person-group><article-title>The association of serum cystatin C with glycosylated hemoglobin in Korean adults</article-title><source>Diabetes Metab J</source><year>2016</year><volume>40</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">26616596</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Prevalence of metabolic syndrome and its components between reduced kidney function and preserved kidney function by estimated glomerular filtration rate (eGFR) based on creatinine (eGFRcr), cystatin C (eGFRcys), and combined creatinine-cystatin C (eGFRcr-cys). (A) Metabolic syndrome, (B) abdominal obesity, (C) hypertension, (D) high fasting glucose, (E) low high density lipoprotein (HDL), (F) high triglyceride, (G) high insulin resistance, and (H) hepatic steatosis. <italic>P</italic> value was calculated by chi-square test. <sup>a</sup><italic>P</italic>&#x0003c;0.05 vs. eGFRcr &#x0003c;60 mL/min/1.73 m<sup>2</sup>; <sup>b</sup><italic>P</italic>&#x0003c;0.05 vs. eGFRcys &#x0003c;60 mL/min/1.73 m<sup>2</sup>; <sup>c</sup><italic>P</italic>&#x0003c;0.05 vs. eGFRcr-cys &#x0003c;60 mL/min/1.73 m<sup>2</sup>.</title></caption><graphic xlink:href="enm-31-446-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinical Characteristics of the Subjects</title></caption><alternatives><graphic xlink:href="enm-31-446-i001"/><table frame="hsides" rules="rows"><col width="30.83%" span="1"/><col width="18.69%" span="1"/><col width="18.69%" span="1"/><col width="18.69%" span="1"/><col width="13.1%" span="1"/><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Total</th><th valign="top" align="center" rowspan="1" colspan="1">Men</th><th valign="top" align="center" rowspan="1" colspan="1">Women</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number</td><td valign="top" align="center" rowspan="1" colspan="1">3,154</td><td valign="top" align="center" rowspan="1" colspan="1">1,871</td><td valign="top" align="center" rowspan="1" colspan="1">1,283</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Age, yr</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">53.2&#x000b1;10.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">53.2&#x000b1;10.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">53.2&#x000b1;10.3</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.961</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Waist circumference, cm</td><td valign="top" align="center" rowspan="1" colspan="1">85.0&#x000b1;9.2</td><td valign="top" align="center" rowspan="1" colspan="1">88.4&#x000b1;7.6</td><td valign="top" align="center" rowspan="1" colspan="1">79.9&#x000b1;8.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Body mass index, kg/m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">23.9&#x000b1;3.0</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">24.5&#x000b1;2.8</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">23.1&#x000b1;3.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td><td valign="top" align="center" rowspan="1" colspan="1">117.8&#x000b1;13.9</td><td valign="top" align="center" rowspan="1" colspan="1">119.2&#x000b1;12.9</td><td valign="top" align="center" rowspan="1" colspan="1">115.7&#x000b1;14.9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Diastolic blood pressure, mm Hg</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">77.4&#x000b1;10.4</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">79.5&#x000b1;10.1</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">74.4&#x000b1;10.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fasting blood glucose, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">98.3&#x000b1;22.5</td><td valign="top" align="center" rowspan="1" colspan="1">101.2&#x000b1;24.6</td><td valign="top" align="center" rowspan="1" colspan="1">93.9&#x000b1;18.3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Insulin, &#x003bc;U/mL</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">4.97&#x000b1;3.23</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">5.11&#x000b1;3.47</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">4.77&#x000b1;2.83</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOMA-IR</td><td valign="top" align="center" rowspan="1" colspan="1">1.24&#x000b1;1.00</td><td valign="top" align="center" rowspan="1" colspan="1">1.31&#x000b1;1.09</td><td valign="top" align="center" rowspan="1" colspan="1">1.14&#x000b1;0.84</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Total cholesterol, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">210.3&#x000b1;38.6</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">209.7&#x000b1;38.9</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">211.2&#x000b1;38.1</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.303</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">129.1&#x000b1;34.9</td><td valign="top" align="center" rowspan="1" colspan="1">130.2&#x000b1;34.6</td><td valign="top" align="center" rowspan="1" colspan="1">127.4&#x000b1;35.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Triglyceride, mg/dL (median)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">129.1&#x000b1;94.4 (106.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">147.0&#x000b1;102.6 (121.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">104.6&#x000b1;74.1 (86.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">55.1&#x000b1;13.7</td><td valign="top" align="center" rowspan="1" colspan="1">51.6&#x000b1;12.3</td><td valign="top" align="center" rowspan="1" colspan="1">60.1&#x000b1;14.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">AST, IU/L</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">28.1&#x000b1;10.9</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">30.0&#x000b1;11.7</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">25.2&#x000b1;9.1</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALT, IU/L</td><td valign="top" align="center" rowspan="1" colspan="1">26.7&#x000b1;16.2</td><td valign="top" align="center" rowspan="1" colspan="1">30.7&#x000b1;17.1</td><td valign="top" align="center" rowspan="1" colspan="1">20.9&#x000b1;12.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">GGT, IU/L (median)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">42.5&#x000b1;46.9 (28.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">55.2&#x000b1;53.3 (39.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">24.0&#x000b1;26.0 (18.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BUN, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">14.1&#x000b1;3.7</td><td valign="top" align="center" rowspan="1" colspan="1">14.6&#x000b1;3.7</td><td valign="top" align="center" rowspan="1" colspan="1">13.4&#x000b1;3.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Creatinine, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.86&#x000b1;0.18</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.97&#x000b1;0.14</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.71&#x000b1;0.13</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Uric acid, mg/dL</td><td valign="top" align="center" rowspan="1" colspan="1">5.7&#x000b1;1.5</td><td valign="top" align="center" rowspan="1" colspan="1">6.4&#x000b1;1.4</td><td valign="top" align="center" rowspan="1" colspan="1">4.7&#x000b1;1.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">hs-CRP, mg/dL (median)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.15&#x000b1;0.35 (0.06)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.17&#x000b1;0.35 (0.07)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.12&#x000b1;0.35 (0.05)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cystatin C, mg/L</td><td valign="top" align="center" rowspan="1" colspan="1">0.85&#x000b1;0.17</td><td valign="top" align="center" rowspan="1" colspan="1">0.89&#x000b1;0.16</td><td valign="top" align="center" rowspan="1" colspan="1">0.80&#x000b1;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Fatty liver index</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">33.3&#x000b1;25.6</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">42.8&#x000b1;24.9</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">19.3&#x000b1;19.4</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFRcr, mL/min/1.73 m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">91.2&#x000b1;13.6</td><td valign="top" align="center" rowspan="1" colspan="1">88.7&#x000b1;13.3</td><td valign="top" align="center" rowspan="1" colspan="1">94.9&#x000b1;13.2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">eGFRcys, mL/min/1.73 m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">96.1&#x000b1;18.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">94.9&#x000b1;18.5</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">97.9&#x000b1;17.5</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFRcr-cys, mL/min/1.73 m<sup>2</sup></td><td valign="top" align="center" rowspan="1" colspan="1">94.5&#x000b1;15.4</td><td valign="top" align="center" rowspan="1" colspan="1">92.5&#x000b1;15.0</td><td valign="top" align="center" rowspan="1" colspan="1">97.5&#x000b1;15.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Metabolic syndrome, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">745 (23.6)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">503 (26.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">233 (18.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001<sup>b</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as mean&#x000b1;SD unless otherwise indicated. <italic>P</italic> value was calculated by independent <italic>t</italic> test unless otherwise indicated.</p><p>HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low density lipoprotein; HDL, high density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, &#x003b3;-glutamyltransferase; BUN, blood urea nitrogen; hs-CRP, high-sensitivity C-reactive protein; eGFRcr, estimated glomerular filtration rate (GFR) from creatinine equation; eGFRcys, estimated GFR from cystatin C equation; eGFRcr-cys, estimated GFR from creatinine-cystatin C equation.</p><p><sup>a</sup>Mann-Whitney test; <sup>b</sup>Chi-square test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>The Prevalence of Reduced Kidney Function by eGFR Based on Creatinine, Cystatin C, and Combined Creatinine-Cystatin C</title></caption><alternatives><graphic xlink:href="enm-31-446-i002"/><table frame="hsides" rules="rows"><col width="29.43%" span="1"/><col width="12.41%" span="1"/><col width="15.4%" span="1"/><col width="15.4%" span="1"/><col width="15.4%" span="1"/><col width="11.95%" span="1"/><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Parameter</th><th valign="top" align="center" rowspan="1" colspan="1">No.</th><th valign="top" align="center" rowspan="1" colspan="1">eGFRcr</th><th valign="top" align="center" rowspan="1" colspan="1">eGFRcys</th><th valign="top" align="center" rowspan="1" colspan="1">eGFRcr-cys</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="right" rowspan="1" colspan="1">1,871</td><td valign="top" align="center" rowspan="1" colspan="1">39 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">66 (3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (2.1)</td><td valign="top" align="right" rowspan="1" colspan="1">0.005</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="right" rowspan="1" colspan="1">1,283</td><td valign="top" align="center" rowspan="1" colspan="1">16 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (2.9)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (1.6)</td><td valign="top" align="right" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Age, yr</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;20&#x02013;39</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">349</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1 (0.3)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.367</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;40&#x02013;59</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">2,007</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">15 (0.7)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">26 (1.3)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">14 (0.7)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.087</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;&#x02265;60</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">798</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">39 (4.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">77 (9.6)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">46 (5.8)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Metabolic syndrome</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1">2,409</td><td valign="top" align="center" rowspan="1" colspan="1">36 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (1.6)</td><td valign="top" align="right" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1">745</td><td valign="top" align="center" rowspan="1" colspan="1">19 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (3.0)</td><td valign="top" align="right" rowspan="1" colspan="1">0.022</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Abdominal obesity</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1,711</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">20 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">32 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">33 (1.5)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.153</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1,443</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">35 (2.4)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">71 (4.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">27 (2.7)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1">2,162</td><td valign="top" align="center" rowspan="1" colspan="1">31 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (1.5)</td><td valign="top" align="right" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1">992</td><td valign="top" align="center" rowspan="1" colspan="1">24 (2.4)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (4.4)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (2.7)</td><td valign="top" align="right" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">High fasting glucose</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">2,169</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">34 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">68 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">40 (1.8)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">985</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">21 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">35 (3.6)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">20 (2.0)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.057</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High triglyceride</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1">2,286</td><td valign="top" align="center" rowspan="1" colspan="1">36 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (2.9)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (1.8)</td><td valign="top" align="right" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1">868</td><td valign="top" align="center" rowspan="1" colspan="1">19 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (2.0)</td><td valign="top" align="right" rowspan="1" colspan="1">0.023</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Low HDL</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;No</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">2,589</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">46 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">70 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">42 (1.6)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.011</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;Yes</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">565</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">9 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">33 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">18 (3.2)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High insulin resistance</td><td valign="top" align="right" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IR &#x02264;75 percentile</td><td valign="top" align="right" rowspan="1" colspan="1">2,366</td><td valign="top" align="center" rowspan="1" colspan="1">32 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (1.6)</td><td valign="top" align="right" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IR &#x0003e;75 percentile</td><td valign="top" align="right" rowspan="1" colspan="1">788</td><td valign="top" align="center" rowspan="1" colspan="1">23 (2.9)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (2.9)</td><td valign="top" align="right" rowspan="1" colspan="1">0.021</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">Hepatic steatosis</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;FLI &#x0003c;30</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1,693</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">21 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">36 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">20 (1.2)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.012</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">&#x02003;FLI &#x02265;60</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">574</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">16 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">28 (4.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">16 (2.8)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.083</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are expressed as number (%). <italic>P</italic> value was calculated by chi-square test.</p><p>eGFR, estimated glomerular filtration rate; eGFRcr, estimated GFR from creatinine equation; eGFRcys, estimated GFR from cystatin C equation; eGFRcr-cys, estimated GFR from creatinine-cystatin C equation; HDL, high density lipoprotein; IR, insulin resistance; FLI, fatty liver index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>ORs (95% CI) of Reduced Kidney Function by eGFR Based on Creatinine, Cystatin C, and Combined Creatinine-Cystatin C for the Prevalence of Metabolic Syndrome</title></caption><alternatives><graphic xlink:href="enm-31-446-i003"/><table frame="hsides" rules="rows"><col width="18.09%" span="1"/><col width="15.76%" span="1"/><col width="11.48%" span="1"/><col width="15.56%" span="1"/><col width="11.48%" span="1"/><col width="16.15%" span="1"/><col width="11.48%" span="1"/><thead><tr><th valign="middle" align="left" rowspan="2" colspan="1">eGFR</th><th valign="top" align="center" rowspan="1" colspan="2">Model 1<sup>a</sup></th><th valign="top" align="center" rowspan="1" colspan="2">Model 2<sup>b</sup></th><th valign="top" align="center" rowspan="1" colspan="2">Model 3<sup>c</sup></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th valign="top" align="center" rowspan="1" colspan="1">OR (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFRcr &#x02265;60</td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">eGFRcr &#x0003c;60</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.75 (1.00&#x02013;3.07)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.050</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.29 (0.72&#x02013;2.29)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.380</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.03 (0.47&#x02013;2.28)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.928</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFRcys &#x02265;60</td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">eGFRcys &#x0003c;60</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.97 (1.30&#x02013;2.96)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.001</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.47 (0.96&#x02013;2.25)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.070</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.57 (0.92&#x02013;2.67)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.094</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFRcr-cys &#x02265;60</td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">eGFRcr-cys &#x0003c;60</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.93 (1.13&#x02013;3.28)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.015</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.42 (0.82&#x02013;2.45)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.203</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">1.42 (0.71&#x02013;2.85)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(237,237,238)">0.315</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>eGFR is expressed as mL/min/1.73 m<sup>2</sup>.</p><p>OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; eGFRcr, estimated GFR from creatinine equation; eGFRcys, estimated GFR from cystatin C equation; eGFRcr-cys, estimated GFR from creatinine-cystatin C equation.</p><p><sup>a</sup>Model 1, non-adjusted; <sup>b</sup>Model 2, adjusted for age and sex; <sup>c</sup>Model 3, adjusted for age, sex, abdominal obesity, and high fasting glucose.</p></fn></table-wrap-foot></table-wrap></floats-group></article>